|Professor Eric Morand|
Improved outcomes for patients with lupus are expected as a result of research funding worth nearly $.75 million, secured by researchers in the (SCS).
Pharmaceutical companies UCB Biopharma SPRL and GlaxoSmithKline (GSK), who are among the leading companies worldwide developing therapies for lupus, are to fund research led by , Head of SCS and Head of Rheumatology at Monash Health, to develop and validate treatment targets in lupus.
“Systemic lupus erythematosus (SLE, or lupus) is a serious multisystem autoimmune disease,” said Professor Morand. “Patients with lupus, usually young women, suffer a loss of life expectancy and in some cases severe illness, caused by the immune system damaging multiple organs.”